Podcasts about gynecology

Ursodiol (ursodeoxycholic acid) is a prescription bile acid medication used to dissolve cholesterol gallstones, prevent gallstones during rapid weight loss, and treat liver diseases like primary biliary cholangitis (PBC) by reducing toxic bile acids and cholesterol production. It works by changing bile composition, making it less saturated with cholesterol, and is available as oral medication. Of course, it is also the foundational medication for treatment of diagnosed Intrahepatic Cholestasis of Pregnancy (ICP). Does this medication reduce adverse perinatal outcomes? In this episode, we will review a new study from the Green Journal, which will be out in February 2026, examining the recurrence risk for ICP using data from NY. In a patient with prior history of ICP, is there any guidance on monitoring of serum bile acids in the subsequent pregnancy before symptoms develop? We will explain. PLUS we will review the data on whether Ursodiol may hold promise in recurrence prevention or in reduction of adverse outcomes once the condition is diagnosed. Listen in for details. 1. 2019: Chappell LC, Bell JL, Smith A, Linsell L, Juszczak E, Dixon PH, Chambers J, Hunter R, Dorling J, Williamson C, Thornton JG; PITCHES study group. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet. 2019 Sep 7;394(10201):849-860. doi: 10.1016/S0140-6736(19)31270-X. Epub 2019 Aug 1. PMID: 31378395; PMCID: PMC6739598. https://pubmed.ncbi.nlm.nih.gov/31378395/2. February 08, 2025: Rahim, Mussarat N et al. Pregnancy and the liver. The Lancet. 2021; Volume 405, Issue 10477, 498 – 513 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02351-1/fulltext3. SMFM CS 53; 20214. Rosenberg, Henri M. MD; Sarker, Minhazur R. MD; Ramos, Gladys A. MD; Bianco, Angela MD; Ferrara, Lauren MD; DeBolt, Chelsea A. MD. Intrahepatic Cholestasis of Pregnancy Recurrence in a Subsequent Pregnancy. Obstetrics & Gynecology 147(2):p 239-241, February 2026. | DOI: 10.1097/AOG.0000000000006033 https://journals.lww.com/greenjournal/fulltext/2026/02000/intrahepatic_cholestasis_of_pregnancy_recurrence.13.aspx5. Ovadia C, Sajous J, Seed PT et al. Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis. Lancet Gastroenterol Hepatol. 2021 Jul;6(7):547-558. doi: 10.1016/S2468-1253(21)00074-1. Epub 2021 Apr 27. PMID: 33915090; PMCID: PMC8192305.6. EASL Clinical Practice Guidelines on the management of liver diseases in pregnancy. European Association for the Study of the Liver; 2023

Behind the Knife ABSITE 2026 – Up-to-date and high yield learning to help you DOMINATE the exam.Don't forget to check out our ABSITE Podcast Companion Book available on Amazon: https://www.amazon.com/Behind-Knife-ABSITE-Podcast-Companion/dp/B0CLDQWZG3/ref=monarch_sidesheetBe sure to check out our free study aid, which includes all 32 review episodes, brief written summaries, high yield images, and flash cards. Simply create an account on our iOS or Android app or on our website and you will find the entire course in your Library. Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Google Play App Store: https://play.google.com/store/apps/details?id=com.btk.appBehind the Knife would like to sincerely thank Medtronic for sponsoring the entire 2026 ABSITE podcast series.  Medtronic has a rich history of supporting surgical education, and we couldn't be happier that they chose to partner with Behind the Knife.  Learn more at https://www.medtronic.com/en-us/index.htmlIf you like the work that Behind the Knife is doing, please leave us a review wherever you listen to podcasts.  Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  Check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium:General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-reviewBehind the Knife in Español - repaso para el examen de certificación en cirugía general: https://app.behindtheknife.org/premium/repaso-para-el-examen-de-certificaci-n-en-cirug-a-general

The ENG implant has data placing it as the most reversible, hormonal contraceptive agent available with a typical use failure rate of 0.05%. Unfavorable bleeding patterns, such as frequent or prolonged bleeding, affect approximately 40% of ENG implant users within the first 3 months but typically improve over time. Nonetheless, it is the main reason for patient discontinuation. In the past, various medications have shown to have at least some short-term reduction in bothersome breakthrough bleeding (BTB). These include doxycycline, ethinyl estradiol (EE), mefenamic acid, combined oral contraceptives (COCs), short term tamoxifen, norethindrone, and ulipristal acetate. In this episode, we will summarize a new RCT (AJOG, released as epub on Jan 7, 2026) which describes the use of TXA for ENG related BTB. Did it work? Listen in for details.1. Andrade, Maíra Cristina Ribeiro et al. Norethisterone for prolonged uterine bleeding associated with etonogestrel implant (IMPLANET): a randomized controlled trialAmerican Journal of Obstetrics & Gynecology, Volume 234, Issue 1, 101 - 1152. Edelman, Alison et al. Treatment of unfavorable bleeding patterns in contraceptive implant users with tranexamic acid: randomized clinical trial. American Journal of Obstetrics & Gynecology, Volume 0, Issue (Articles in Press January 07, 2026)

In vitro fertilization, or IVF, can cost upwards of $20,000 in California — for one cycle. For that reason, it's put financial strain on many California families and been completely out of reach for others, including couples who have faced insurance denials because they are LGBTQ+. But a California law that went into effect this month, SB 729, requires large employer-sponsored health plans to cover up to three cycles of IVF, along with other infertility services, regardless of sexual orientation. We'll hear what the new law means for family planning in California, and for you: Does this put IVF within reach for you? What's been your experience with IVF? Guests: Caroline Menjivar, member of the California State Senate representing the 20th district (San Fernando Valley) Shefali Luthra, reproductive health reporter, The 19th Sarah Jolly, has been trying to conceive with her husband for five years Dr. Alexander Quaas, medical director Shady Grove Fertility San Diego; fertility specialist; wrote an article for the American Journal of Obstetrics & Gynecology titled, “The California infertility insurance mandate: another step toward reproductive justice?” Learn more about your ad choices. Visit megaphone.fm/adchoices

If you go by pop culture depictions, menopause seems like no big deal — a few hot flashes, some comical bouts of hormone-fueled rage, and the “big change,” as it was once called, is over. But for many of the 2 million American women who enter menopause each year, the symptoms can be a lot more serious and long-lasting, ranging from vertigo and joint pain to brain fog and heart problems.On this episode, we take a deep dive into perimenopause and menopause – what's going on biologically? What can be done to ease symptoms? And why do so many women struggle to receive help from their doctors?We talk with menopause experts about hormone replacement therapy, and why it was demonized for many years; find out what researchers have discovered about the causes of brain fog; and hear about new efforts to deal with medically induced menopause. In this excerpt from our live event, Reimagining Menopause, host Maiken Scott talks with two certified menopause providers — Robyn Faye, an OB-GYN at Jefferson Health in Philadelphia, and Arina Chesnokova, assistant professor in of Obstetrics and Gynecology at the University of Pennsylvania's Perelman School of Medicine — about the ins and outs of hormone therapy, which symptoms it alleviates, when it's safe and when it's not. Watch the full discussion here. Reporter Alan Yu talks with researchers about what's behind one of the most vexing symptoms of menopause for many women — brain fog. For women who have cancer when they're younger, especially breast or ovarian cancer, chemotherapy and other medications needed to treat the disease can affect hormones - and suddenly plunge them into menopause, years before they might naturally experience it. We explore what their options are, and why so many say they were not prepared for this change.

A Podcast from Obstetrics & Gynecology highlighting the latest research and practice updates in the field. This episode features an interview with Dr. Ann Oluloro, author of "Association Between Comorbidity and Clinical Trial Enrollment for Patients With Uterine Cancer."

It's a controversial topic: the impact of uterine incision (hysterectomy) on the neonate delivery interval (also called the U-D interval). Does it matter? Just to be clear, we're talking about time from uterine entry to fetal extraction, not skin incision to fetal extraction. Past publications have produced conflicting results, often limited by small sample sizes, heterogeneous indications for delivery, and reliance on surrogate markers (like apgar scores) rather than clinical morbidity. But a new study published in the Gray journal at the end of 2025 (December 30, 2025) gives some new insights. In this episode, we will review this retrospective study and play the “Devil's advocate” as we summarize the rebuttal data. As the reports are conflicting, we will end the podcast with a real-world interpretation and application of this data. Listen in for details. 1. Bart, Yossi et al. Uterine Incision-to-Delivery Interval and Neonatal Outcomes among Non-urgent, Term, Cesarean Deliveries. American Journal of Obstetrics & Gynecology, Volume 0, Issue 0. https://www.ajog.org/article/S0002-9378(25)00980-9/fulltext?rss=yes2. Maayan-Metzger A, Schushan-Eisen I, Todris L, Etchin A, Kuint J. The effect of time intervals on neonatal outcome in elective cesarean delivery at term under regional anesthesia. Int J Gynaecol Obstet. 2010 Dec;111(3):224-8. doi: 10.1016/j.ijgo.2010.07.022. Epub 2010 Sep 19. PMID: 20855070. https://pubmed.ncbi.nlm.nih.gov/20855070/3. Spain JE, Tuuli M, Stout MJ, Roehl KA, Odibo AO, Macones GA, Cahill AG. Time from uterine incision to delivery and hypoxic neonatal outcomes. Am J Perinatol. 2015 Apr;32(5):497-502. doi: 10.1055/s-0034-1396696. Epub 2014 Dec 24. PMID: 25539409.4. Bader AM, Datta S, Arthur GR, Benvenuti E, Courtney M, Hauch M. Maternal and fetal catecholamines and uterine incision-to-delivery interval during elective cesarean. Obstet Gynecol. 1990 Apr;75(4):600-3. PMID: 2107478.5. Tekin, E., Inal, H.A. & Isenlik, B.S. A Comparison of the Effect of Time from Uterine Incision to Delivery on Neonatal Outcomes in Women with One Previous and Repeat (Two or More) Cesarean Sections. SN Compr. Clin. Med. 5, 80 (2023). https://doi.org/10.1007/s42399-023-01427-x

In this conversation, Dr. Tomer Singer shares his personal journey into reproductive medicine, influenced by his family's struggles with infertility. He discusses the unique challenges faced by Orthodox couples in fertility treatments and the importance of community engagement. The conversation also covers the rise of egg freezing as a viable option for women, the optimal age for freezing eggs, and the success rates of frozen eggs. Dr. Singer emphasizes the role of nutrition and AI in improving patient care and outcomes in reproductive medicine. He concludes with thoughts on the future of fertility treatments.Chapters00:00 The Journey into Fertility Medicine02:50 Understanding Orthodox Fertility Practices05:39 Navigating Religious and Medical Collaboration08:54 Education and Communication in Fertility11:40 The Rise of Egg Freezing15:01 Optimal Age for Egg Freezing17:58 Success Rates of Frozen Eggs20:39 Improving Egg Quality and Patient Health23:59 Future of Egg Freezing Technology29:51 Understanding the Costs of Egg Freezing32:59 The Importance of Egg Freezing for Future Fertility34:08 The Age Visit: A New Approach to Women's Health38:18 The Role of AI in Reproductive Medicine41:25 Job Security in the Age of AI45:23 Future Trends in Fertility Treatments48:46 Rapid Fire Questions on Fertility Practices52:28 Prioritizing Mental Health in a Busy Life54:25 Connecting with Dr. SingerAbout Dr. Tomer Singer:Tomer Singer, MD, MBA is an internationally renowned Endocrinologist and Infertility Specialist. He serves as the System Chief of Reproductive Endocrinology and Infertility at Northwell Health where he is responsible for programmatic strategy and fosters academic and clinical growth. Dr. Singer earned his medical degree from the Sackler School of Medicine and an MBA in Health Care Management from the Hofstra Zarb School of Business. He is double board- certified in Obstetrics and Gynecology and Reproductive Endocrinology and Infertility. He is an Associate Professor of OB/GYN at the Donald and Barbara Zucker School of Medicine. Dr. Singer has produced numerous publications, chapter reviews, and given presentations nationally and internationally in the field of Infertility, Reproductive Endocrinology, IVF, Pre-Implantation Genetic Testing (PGT), Egg Freezing, Egg Donation, and Gestational Surrogacy. He has performed hundreds of minimally invasive surgical procedures including laparoscopies and hysteroscopies. Dr. Singer has held several senior roles at Lenox Hill Hospital where he served as the Director of Reproductive Endocrinology and Infertility, the Vice Chairman of the Department of OB/GYN, Director of Egg Freezing, and the OB/GYN Residency Program Director. Dr. Singer's commitment to helping thousands of patients has earned him several awards including the Castle Conolly Top Doctor Award every year since 2017. Contact Dr. Tomer SingerInstagram @tsingermd

Doctors have long recommended regular cervical cancer screenings. Traditionally doctors perform these exams using a speculum, which often say is uncomfortable and, for many, quite painful. Some recent developments could make a large number of these screenings easier. In early January, the Health Resources and Services Administration, which is part of the Department of Health and Human Services, updated its guidelines to say that self-administered tests are an acceptable way to screen for human papillomavirus. HPV is a sexually-transmitted disease that causes the majority of cervical cancer cases. OB-GYNs are hopeful that at-home testing will make cervical cancer screenings easier to access…. and significantly more comfortable. Guests: Dr. Linda Eckert, professor of Obstetrics and Gynecology at the University of Washington School of Medicine Related links: New Guidelines Endorse Self-Swab Alternative to Pap Smear for Cervical Cancer Testing - The New York Times Cervical Cancer Risk Factors | Cervical Cancer | CDC The FDA has approved an at-home HPV test. What you need to know : NPR Thank you to the supporters of KUOW, you help make this show possible! If you want to help out, go to kuow.org/donate/soundsidenotes Soundside is a production of KUOW in Seattle, a proud member of the NPR Network.See omnystudio.com/listener for privacy information.

In this episode of Parts and Labor, Angela Chaudhari, MD, hosts a panel of experts from Northwestern Medicine's Division of Gynecologic Oncology to discuss the groundbreaking research and clinical trials shaping the future of gynecologic cancer care. The panel explores innovations in immunotherapy, investigator-initiated trials, survivorship and symptom science, while highlighting efforts to expand access and diversity in clinical research across Chicago and the surrounding suburbs.This episode's panel of guests includes:• Emma L. Barber, MD, John and Ruth Brewer Professor of Gynecology and Cancer Research, Division Chief of Gynecologic Oncology and Director of Robotic Surgery• Daniela E. Matei, MD, Diana, Princess of Wales Professor of Cancer Research and Chief of Reproductive Science in the Departments of Obstetrics and Gynecology and Hematology and Oncology• Dario R. Roque, MD, Associate Professor of Gynecologic Oncology and Fellowship Program Director• Emily M. Hinchcliff, MD, Assistant Professor of Gynecologic Oncology and Program Director of the OB-GYN Residency Program

Skin Deep: How Melanin Impacts Your Body's Response To DrugsScientific research is becoming more inclusive, but one area that's still lacking this diversity is pre-clinical research. Without knowing how medications will react to different ancestries and skin tones, millions of people are being put at risk. Our experts discuss the effect melanin has on a drug's efficacy and changes the industry can implement right now that will make a big difference.  Does Birth Control Cause PCOS? Facts And Misconceptions Of The Disorder  Polycystic ovarian syndrome affects at least one in ten women – probably more since it's so underdiagnosed. Sadly, many women are told that having PCOS means they'll never become pregnant. However, our expert this week dispels this and other misinformation that's widespread about PCOS.  Medical Notes: Robots Are Outperforming Doctors, The Dangerous Additives In Ultra-Processed Foods, And How Happiness Supports Your Brain HealthHow scientists could catch Schizophrenia sooner than ever before. Ultra-processed foods may be raising your blood sugar levels. How happiness supports your brain health. Are robots better doctors? Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Does Birth Control Cause PCOS? Facts And Misconceptions Of The Disorder  Polycystic ovarian syndrome affects at least one in ten women – probably more since it's so underdiagnosed. Sadly, many women are told that having PCOS means they'll never become pregnant. However, Dr. Lora Shahine dispels this and other misinformation that's widespread about PCOS.  Host: Greg Johnson.  Producers: Kristen Farrah.  Guests: Dr. Lora Shahine, Double Board-Certified Reproductive Endocrinologist and Infertility Specialist, Pacific Northwest Fertility, Podcast Host, Baby or Bust Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Uterine rupture or dehiscence associated with TOLAC results in the most significant increase in the likelihood of additional maternal and neonatal morbidity. It should be noted that the terms “uterine rupture” and “uterine dehiscence” are not consistently distinguished from each other in the literature and often are used interchangeably. Furthermore, the reported incidence of uterine rupture varies in part because some studies have grouped true, catastrophic uterine rupture together with asymptomatic scar dehiscence. In January 2026, a new meta-analysis examines the relationship between oxytocin use with TOLAC and uterine rupture. In this episode, we will summarize the key findings in that study and review the data on the use of internal monitors during TOLAC. Do internal monitors (FSE, IUPC) offer a safer TOLAC compared with external monitors? Listen in for details.1. Nicolì, Pierpaolo et al.Oxytocin dosing during trial of labor after cesarean to minimize the risk of uterine rupture: a systematic review and meta-analysisAmerican Journal of Obstetrics & Gynecology MFM, Volume 8, Issue 1, 1018462. Practice Bulletin No. 184: Vaginal Birth After Cesarean Delivery. Obstetrics & Gynecology 130(5):p e217-e233, November 2017. | DOI: 10.1097/AOG.00000000000023983. ACOG Clinical Practice Guideline No. 10:Intrapartum Fetal Heart Rate Monitoring: Interpretation and Management. Obstetrics & Gynecology 146(4):p 583-599, October 2025. | DOI: 10.1097/AOG.00000000000060494. Bruno AM, Allshouse AA, Metz TD. Maximum Oxytocin Dose and Uterine Rupture During Trial of Labor After Cesarean. Obstet Gynecol. 2025 Dec 1;146(6):843-850. doi: 10.1097/AOG.0000000000006106. Epub 2025 Oct 30. PMID: 41325062.

In this episode, Dr. Blythe Bynum joins the show to discuss her new article titled Navigating Choices: Pregnancy Options Counseling Experiences in Individuals With Opioid Use Disorder, featured in the November/December issue of the Journal of Addiction Medicine. Dr. Blythe Bynum is an assistant professor in the Department of Obstetrics and Gynecology at Thomas Jefferson University in Philadelphia, Pennsylvania. She is a board certified OBGYN with fellowship training in Complex Family Planning.    Article Link: Navigating Choices: Pregnancy Options Counseling Experiences in Individuals With Opioid Use Disorder

In 2002, the National Institute of Child Health and Human Development (NICHD) proposed the 3-Tier fetal heart rate (FHR) classification system that was subsequently adopted by many organizations, categorizing tracings into three groups: Category I (normal), Category II (indeterminate), and Category III (abnormal). Recently, our podcast team received an interesting question form one of our podcast family members: “If there is a change in the fetal heart rate tracing intrapartum, but it is still in the normal range (like 120 going to 150)- and variability is normal, is that an abnormality? And what is meant by a ‘ZigZag' FHT pattern (different than marked variability)?”. That is a fantastically complex question…and we will explain the answer in this episode.1. Zullo F, Di Mascio D, Raghuraman N, Wagner S, Brunelli R, Giancotti A, Mendez-Figueroa H, Cahill AG, Gupta M, Berghella V, Blackwell SC, Chauhan SP. Three-tiered fetal heart rate interpretation system and adverse neonatal and maternal outcomes: a systematic review and meta-analysis. Am J Obstet Gynecol. 2023 Oct;229(4):377-387. doi: 10.1016/j.ajog.2023.04.008. Epub 2023 Apr 11. PMID: 37044237.2. Ghi T, Di Pasquo E, Dall'Asta A, et al. Intrapartum Fetal Heart Rate Between 150 and 160 BPM at or After 40 Weeks and Labor Outcome.Acta Obstetricia Et Gynecologica Scandinavica. 2021;100(3):548-554. doi:10.1111/aogs.14024.3. The 3 Tier System: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://ncc-efm.org/filz/NICHD_Reference_from_CCPR.pdf4. Jia YJ, Ghi T, Pereira S, Gracia Perez-Bonfils A, Chandraharan E. Pathophysiological Interpretation of Fetal Heart Rate Tracings in Clinical Practice. American Journal of Obstetrics and Gynecology. 2023;228(6):622-644. doi:10.1016/j.ajog.2022.05.0235. Ghi T, Di Pasquo E, Dall'Asta A, et al. Intrapartum Fetal Heart Rate Between 150 and 160 BPM at or After 40 Weeks and Labor Outcome. Acta Obstetricia Et Gynecologica Scandinavica. 2021;100(3):548-554. doi:10.1111/aogs.14024.6. Yang M, Stout MJ, López JD, Colvin R, Macones GA, Cahill AG. Association of Fetal Heart Rate Baseline Change and Neonatal Outcomes. Am J Perinatol. 2017 Jul;34(9):879-886. doi: 10.1055/s-0037-1600911. Epub 2017 Mar 16. PMID: 28301895.

Podcast Family, in our immediate past episode we tackled the discrepancy that is often found between a clinical diagnosis of intra-amniotic infection/chorioamnionitis and histological chorioamnionitis. From that episode, we received a fantastic question from one of our podcast family members: Can a patient have IAI without fever? That question is really deep and highlights a gap in the current diagnostic scheme/ criteria from the ACOG. Listen in for details!1. ACOG CO 7122. Sukumaran S, Pereira V, Mallur S, Chandraharan E. Cardiotocograph (CTG) Changes and Maternal and Neonatal Outcomes in Chorioamnionitis and/­or Funisitis Confirmed on Histopathology. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2021. C3. Romero R, Chaemsaithong P, Korzeniewski SJ, et al. Clinical Chorioamnionitis at Term III: How Well Do Clinical Criteria Perform in the Identification of Proven Intra-Amniotic Infection? Journal of Perinatal Medicine. 2015.

Episode: 2834 Wombs and Witchcraft: Edward Jorden's Suffocation of the Mother (1603).  Today, wombs and witchcraft.

Join Katlyn Moss and Dr. Suzanne Dixon for this special episode created with patients in mind!  Sometimes it's hard for patients to open up and discuss their health care needs and questions with their OB/GYN when it comes to symptoms such as irregular periods, painful periods and heavy bleeding. They will highlight some of the most common conditions and treatments throughout the phases of life, from the teenage years through menopause.   We would love your feedback on our podcast!  Please take our listener survey to provide your comments.Follow us on FacebookFollow us on InstagramMusic credit: "Carefree" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 Licensehttp://creativecommons.org/licenses/by/4.0/Please provide feedback here:https://redcap.mahec.net/redcap/surveys/?s=XTM8T3RPNK

Anne Zink is a lecturer and senior fellow at the Yale School of Public Health. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. A.B. Zink, N.C. McCann, and R.P. Walensky. From Crisis to Action — Policy Pathways to Reverse the Rise in Congenital Syphilis. N Engl J Med 2025;393:2388-2391.

This episode brings together the science, the medicine, and the lived experience behind BRCA mutations.  Emily Goldberg, JScreen's Director of Genetic Counseling Services, breaks down what these mutations are, how they're inherited, and what the actual cancer risks look like. Dr. Melissa Frey, a GYN oncologist at Cornell who works closely with high-risk families, walks us through what happens after someone tests positive — from screening to risk-reducing surgeries to the big conversations around fertility and timing. We also hear from Heather Boussi, who shares her powerful story of living with both BRCA1 and BRCA2 mutations. She talks about diagnosis, surveillance, surgeries, and how this all shaped her family-building decisions. Lastly, we look at what BRCA means for men, how that journey differs, and why PGT can still be an option. If you or someone you love is navigating this, we close with places to turn for support: JScreen, Sharsheret, I Was Supposed To Have A Baby, and Stardust (links below). It's a mix of expertise, honesty, and heart — the kind of conversation so many people wish they had heard earlier, especially when faced with such difficult decisions.  Note: This episode is the 4th of a series of 5 that we are collaborating on with Jscreen in 2025.  Take a look at our previous three episodes here : Episode 157: Introduction to Genetics and Infertility Episode 166: Fragile X Syndrome: A Silent Factor in Infertility Episode 185: It's Not Just Her: Male Factor Fertility and Genetics Uncovered Resources: Genetics and Personalized Cancer Prevention Program Facing Our Risk Empowered (FORCE) Jewish Fertility Foundation Stardust Foundation Sharsheret JScreen More about Emily Goldberg: Emily Goldberg serves as the Director of Genetic Counseling Services at jscreen, where she is dedicated to helping individuals understand and manage their genetic health. With dual bachelor's degrees in biology and psychology from Brandeis University and a master's degree in Human Genetics from Sarah Lawrence College, Ms. Goldberg has been a certified genetic counselor since 2011. Prior to joining jscreen, she worked at Montefiore Medical Center in the Bronx, specializing in prenatal and cancer genetics. In addition to her role at jscreen, Ms. Goldberg is committed to education, serving as an Instructor at the Albert Einstein College of Medicine and adjunct faculty at Sarah Lawrence College, where she teaches and mentors future genetic counselors. Her expertise and dedication make her a key member of the jscreen team. Connect with JScreen: - visit their website here - check out their Instagram   More about Melissa Frey, MD: Dr. Melissa Frey is an Associate Professor of Obstetrics and Gynecology in the division of Gynecologic Oncology and the Director of the Genetics and Personalized Cancer Prevention Program at Weill Cornell Medicine / NewYork Presbyterian Hospital. Dr. Frey's clinical care and research focus on the management of individuals with hereditary cancer syndromes (e.g. BRCA1, BRCA2, Lynch syndrome) and strong family history of breast and gynecologic cancers. She performs gynecologic cancer risk-reducing surgeries and is the principal investigator on several large trials aimed at cancer prevention among high-risk individuals. Dr. Frey has presented her research at national and international meetings and has more than 130 publications in peer-reviewed scientific journals. Connect with Dr. Melissa Frey: - check out her Instagram - view the Genetics and Personalized Cancer Prevention Program website   More about Heather Boussi :  Heather grew up in Westchester, NY and now lives in Englewood, NJ with her husband and three children. Her personal experience with hereditary cancer risk and genetic testing has made her a passionate advocate for awareness, education, and empowerment in women's health. Grounded in faith and family, Heather shares her story to help others approach life's challenges with strength, perspective, and gratitude. Connect with Heather: - check out Heather's Instagram   Connect with us: -Check out our Website -Follow us on Instagram and send us a message -Watch our TikToks -Follow us on Facebook -Watch us on YouTube -Connect with us on LinkedIn

Guest: Brian Slomovitz, MD Endometrial cancer is closely tied to modifiable risk factors such as obesity, diabetes, hypertension, and insulin resistance—all components of a chronic inflammatory state that heightens cancer susceptibility. Dr. Brian Slomovitz discusses how lifestyle interventions and emerging therapies may reduce cancer recurrence. He's the Director of Gynecologic Oncology and Co-Chair of the Cancer Research Committee at Mount Sinai Medical Center as well as a Professor of Obstetrics and Gynecology at Florida International University in Miami.

Guest: Brian Slomovitz, MD Endometrial cancer is rising in incidence, with mortality now surpassing that of ovarian cancer. Hear from Dr. Brian Slomovitz as he explores evolving molecular classifications, treatment challenges, and the urgent need to address racial disparities in care. Dr. Slomovitz is the Director of Gynecologic Oncology and Co-Chair of the Cancer Research Committee at Mount Sinai Medical Center as well as a Professor of Obstetrics and Gynecology at Florida International University in Miami.

Send us a textCervical cancer is the fourth most common cancer in women globally, according to the World Health Organization. It's preventable and curable as long as it's detected early and managed effectively. Our guest expert for this episode is Salvatore LoCoco, M.D., chair of the School of Medicine's Department of Obstetrics and Gynecology. LoCoco explains what is cervical cancer, which populations are at greatest risk for cervical cancer, screenings, treatment, vaccinations and prevention.

Major health organizations, including the CDC and ACOG, recommend universal Hepatitis C Virus (HCV) screening for all pregnant women during each pregnancy and at time of delivery. Ideally, pregnant women should be screened for hepatitis C virus infection at the first prenatal visit of each pregnancy. If the antibody screen result is positive, hepatitis C virus RNA polymerase chain reaction testing is done to confirm the diagnosis. The risk of perinatal transmission of HCV is up to 9%, with at least one-third of transmissions occurring antenatally. While antiviral therapy is recommended for Hepatitis B in pregnancy with a viral load greater than 200,000 international units/mL to decrease the risk of vertical transmission, the same is not the case for Hep C. According to the ACOG CPG #6 from September 2023, there are no standard treatment protocols for Hep C in pregnancy but a new publication from the PINK journal (7 Dec 2025) is calling for a change. That new publication is, “Hepatitis C Treatment During Pregnancy: Time for a Practice Change”. Listen in for details. 1. ACOG CPG #6; Sept 20262. Bhattacharya D, Aronsohn A, Price J, Lo Re V. Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2023;:ciad319. doi:10.1093/cid/ciad319.3. Chappell CA, Kiser JJ, Brooks KM, et al. Sofosbuvir/¬Velpatasvir Pharmacokinetics, Safety, and Efficacy in Pregnant People With Hepatitis C Virus. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2025;80(4):744-751. doi:10.1093/cid/ciae595.4. Reau N, Munoz SJ, Schiano T. Liver Disease During Pregnancy. The American Journal of Gastroenterology. 2022;117(10S):44-52. doi:10.14309/ajg.0000000000001960.5. Dutra, Karley et al. Hepatitis C Treatment During Pregnancy: Time for a Practice Change. American Journal of Obstetrics & Gynecology MFM, Volume 0, Issue 0, 1018656. Society for Maternal-Fetal Medicine Consult Series #56: Hepatitis C in Pregnancy-Updated Guidelines: Replaces Consult Number 43, November 2017. Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org, Dotters-Katz SK, Kuller JA, Hughes BL. American Journal of Obstetrics and Gynecology. 2021;225(3):B8-B18. doi:10.1016/j.ajog.2021.06.008

At my monthly Ask Me Anything Webinars,  I always get questions about hormone therapy- when to start, when to stop, if the dose should be changed as women get older, and what to do if someone continues to have symptoms or continues to bleed…  In this episode, Dr. Risa Kagan and I answer submitted questions.  We start by briefly running through the established indications for starting menopausal hormone therapy (MHT), and then Dr. Kagan and I discuss the “what ifs” of hormone therapy.   Do you have to wait for 12 months without a period before starting MHT? If someone is taking birth control pills for control of perimenopause symptoms, at what point should they go off? And can they immediately transition to MHT or do they need to take a break and make sure they are no longer making estrogen? A  woman with severe hot flashes is having all day, all night hot flashes- how long is it going to take to get some relief?  Does it matter if it is oral or transdermal as far as the onset of action?  What are the chances of getting 100% relief?   If someone has started MHT but is still having flashes, how long should they wait before adjusting it?  What is the best starting dose if someone has severe flashes? High or low? A woman wrote in that she has been using a 0.75 patch, but continues to have severe flashes.  She got a serum level, and it is 10. Her doctor is reluctant to increase her dose. What would you tell her? A woman has tried four different protocols and has nuisance bleeding with all.  She had an ultrasound and biopsy, and it was all normal. She wants to continue MHT, but is tired of the bleeding. She wants to know which protocol is the least likely to cause bleeding An internist told a woman that after 5 years, it is time to go off her MHT.  What about if she is primarily taking it for hot flashes- how likely is it that her hot flashes will return?  What about if she is primarily on it for bone health (known osteopenia) and joint pain-? What about if she is primarily taking it for sexual benefits? (Libido, lubrication, orgasm) ? What about if she is primarily taking it because she is worried about dementia A woman decided to go off HT since she was only taking it for hot flashes and is now 10 years out. Her manicurist told her that she should taper; otherwise, her flashes will come back. Her gyne says, stop. What does Dr. Kagan say? A 60 year old woman started estrogen when she had a hysterectomy and ovary removal. She was told by her internist that there is no way she will still be having hot flashes in her 60s, and therefore no reason to continue her estrogen. Is that correct? What is the likelihood that she will still be having hot flashes in her 60s or 70s?  The next question is from a woman who increased her oral estradiol to 2 mg to get rid of her flashes,  but is still taking her original Prometrium dose 100 mg. Is that enough to protect the lining of her uterus? When do you increase it? A question from a Substack reader- “I used estradiol gel for 8 years at the start of menopause. I decided to stop it and did so for 3 years; however, my hot flashes (sleep, mood, etc) were relentless and violent. I decided to start again after a 3-years hiatus and at the age of 65. I feel so much better. Is this a problem having stopped and then started again a few years later?”  How can you tell the effectiveness of the HRT you're taking (other than no more hot flashes?) I still feel lack of motivation, low libido, joint aches and I'm so much slower running (1 min+/mile).  (What this really comes down to, is what are realistic expectations for what HT will do?)  How long can a postmenopausal woman stay on testosterone, estrogen and Progesterone?  Let's say a woman has been using a .05 estradiol patch but her skin is really irritated and has decided to try the spray instead.  What is the equivalent dose? A woman with a hysterectomy who is taking estrogen alone has been taking a 1 mg estradiol pill. She has decided to switch to conjugated equine estrogen since she would like breast protection.  Is that correct thinking? If she is going to make the switch, what is the equivalent dose?  A 51 year old is no longer having hot flashes but wants to continue her transdermal estrogen since she has low bone mass and is worried about progression to osteoporosis. What is the minimum dose of estradiol to ensure that she is getting maximum bone protection?  Many questions came in about initiating hormone therapy after age 65... Dr. Risa Kagan is a Clinical Professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at the University of California, San Francisco, and a consulting gynecologist with Sutter Health.  Other episodes with Dr. Kagan Episode 114- Is Duovee the Ideal Hormone Therapy? Episode 175 Your Bones On and Off Estrogen When an IUD is Your Post Menopause Plan

In this episode of Parts and Labor, Angela Chaudhari, MD, hosts a panel of experts from Northwestern Medicine's Division of Gynecologic Oncology to explore the innovative role of robotic surgery in cancer care. The discussion highlights how robotic technology is improving outcomes for patients with gynecologic cancers through minimally invasive techniques, enhanced precision and interdisciplinary collaboration.The panel covers advancements in robotic systems, patient populations who benefit most from this approach, including those with high BMI, complex surgical histories, and fertility concerns, as well as the future of surgical innovation at Northwestern Medicine.This episode's panel of guests includes:• Emma L. Barber, MD, John and Ruth Brewer Professor of Gynecology and Cancer Research, Division Chief of Gynecologic Oncology and Director of Robotic Surgery.• Dario R. Roque, MD, Associate Professor of Gynecologic Oncology and Fellowship Program Director.• Jenna Z. Marcus, MD, Associate Professor of Gynecologic Oncology, Director of Robotic Simulation and Associate Fellowship Program Director.

In the original Løvset maneuver (described for breech presentations), the fetus is rotated in one direction to facilitate arm delivery. For shoulder dystocia, the reverse Løvset applies rotation in the opposite direction—specifically rotating the posterior shoulder toward a "belly down" position through up to 180 degrees of rotation. These maneuvers were first described by Norwegian obstetrician Jørgen Løvset in the 1940s. Now, in the current November 2025 AJOG, this maneuver is back in the spotlight. In this episode, we will review the reverse Løvset maneuver for shoulder dystocia and review its effectiveness. Which maneuver is more likely to result in fetal brachial plexus injury? Listen in for details. 1. A critical evaluation of the external and internal maneuvers for resolution of shoulder dystocia, March 2024; AJOG. https://www.ajog.org/article/S0002-9378(23)00022-4/fulltext2. Grindheim, Sindre et al.Reverse Løvset maneuver for shoulder dystocia, American Journal of Obstetrics & Gynecology, Volume 233, Issue 5, 505.e1 - 505.e43. Leung TY, Stuart O, Suen SS, Sahota DS, Lau TK, Lao TT. Comparison of perinatal outcomes of shoulder dystocia alleviated by different type and sequence of manoeuvres: a retrospective review. BJOG. 2011 Jul;118(8):985-90. doi: 10.1111/j.1471-0528.2011.02968.x. Epub 2011 Apr 12. PMID: 21481159.4. Grobman WA, Miller D, Burke C, Hornbogen A, Tam K, Costello R. Outcomes associated with introduction of a shoulder dystocia protocol. Am J Obstet Gynecol. 2011;205(6):513−517.STRONG COFFEE PROMO CODE:https://strongcoffeecompany.com/discount/CHAPANOSPINOBG

Gynecology surgery presents unique challenges that require preparation, precision, and strong clinical awareness. In this new First Case: Articles on the Go episode, Lindsay Joyce, MSN, RN, CNOR, shares 10 essential insights every perioperative professional should know before stepping into a GYN case, from preventing nerve injuries and ensuring privacy to managing equipment and verifying complex specimens. If you support gynecology procedures or lead teams who do, this quick, practical rundown is worth your time. Here's what you need to know to set your team and your patient up for success!

Misoprostol, as an E1 prostaglandin, is primarily used in obstetrics for cervical ripening (when the Bishop Score is under 6) and/or for labor INDUCTION (to begin labor). IV oxytocin is the principal agent used to augmentlabor, as needed, once labor has begun. In the US, misoprostol is not typically used after 4-6 cm cervical dilation. However, in a patient who requires augmentation,and who declines Pitocin while asking or oral misoprostol, can that be used? Is that evidence-based? The data may surprise you. Listen in for details. 1.     SOGC Guideline No. 432c: Induction of Labour Robinson,Debbie Campbell, Kim Hobson, Sebastian R. MacDonald, W. Kim Sawchuck, DianeWagner, Brenda et al. Journal of Obstetrics and Gynaecology Canada , Volume 45, Issue 1, 70 - 77.e32.     Bracken H, Lightly K, Mundle S, et al. OralMisoprostol Alone Versus Oral Misoprostol Followed by Oxytocin for Labour Induction in Women With Hypertension in Pregnancy (MOLI): Protocol for a Randomised Controlled Trial. BMC Pregnancy and Childbirth. 2021;21(1):537.doi:10.1186/s12884-021-04009-8.3.     Bleich AT, Villano KS, Lo JY, et al. OralMisoprostol for Labor Augmentation: A Randomized Controlled Trial. Obstetrics and Gynecology. 2011;118(6):1255-1260. doi:10.1097/AOG.0b013e318236df5b.4.     Ho M, Cheng SY, Li TC. Titrated Oral MisoprostolSolution Compared With Intravenous Oxytocin for Labor Augmentation: A Randomized Controlled Trial. Obstetrics and Gynecology. 2010;116(3):612-618. doi:10.1097/AOG.0b013e3181ed36cc. STRONG COFFEE PROMO CODE:https://strongcoffeecompany.com/discount/CHAPANOSPINOBG

In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Hydatidiform Mole⁠⁠⁠⁠⁠ from the Gynecology section at ⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

Dr. McCarthy is a board certified Reproductive Endocrinologist practicing at the South Florida Institute for Reproductive Medicine in Jupiter, Florida.  Dr McCarthy completed her undergraduate work at Dartmouth before attending medical school at the University of Michigan where she graduated with distinction in research.  Dr. McCarthy completed a residency in Obstetrics and Gynecology and a clinical and research fellowship in Reproductive Endocrinology and Infertility at the University of Michigan Medical Center. She is one of only a handful of physicians selected by the American Board of Obstetrics and Gynecology to complete her training as a combined, 6 year residency/fellowship. After completing her training in 2010, Dr McCarthy moved to Florida because, after growing up in New England and training in Michigan, she was tired of not being able to feel her fingers.  She loves living in South Florida with her husband and 2 grown children.  Dr McCarthy focuses on providing her patients with patient-centered care with a personal touch.  She is an active member of the American Society for Reproductive Medicine (ASRM), the Society for Reproductive Endocrinology and Infertility (SREI), and the American Congress of Obstetricians and Gynecologists (ACOG). She is an ad-hoc reviewer for ASRM and the International Journal of Obstetrics and Gynecology. 

In this powerful episode of the Conscious Fertility Podcast, Dr. Lorne Brown welcomes renowned reproductive endocrinologist Dr. Natalie Crawford for a deeply informative conversation on fertility, inflammation, hormonal health, and the science behind optimizing egg and sperm quality. Dr. Crawford shares her personal journey through recurrent pregnancy loss, her evidence-based whole-body approach to fertility care, and the foundations of her upcoming book The Fertility Formula. Together, they break down how inflammation, lifestyle, stress, and metabolic health shape reproductive potential — and why fertility is not a mystery, but a formula you can influence.Key takeaways:Inflammation is a major driver of poor egg and sperm quality, hormone imbalance, and implantation challenges — but it is modifiable.Cycle tracking matters: luteal phase length and symptoms can offer early clues about hormonal and metabolic health long before bloodwork changes.Egg quality is not only about age — metabolic and inflammatory factors significantly influence cellular function.Stress and cortisol imbalance contribute to insulin resistance and inflammation, directly affecting fertility in both men and women.Lifestyle choices — sleep, movement, nutrition, toxin exposure, and emotional health — are central pillars of the “fertility formula.”Dr. Natalie Crawford Bio:Natalie Crawford, is a MD who is board certified in both Obstetrics and Gynecology and Reproductive Endocrinology and Infertility and is co-founder of Fora Fertility, a boutique fertility practice in Austin, Texas. Dr. Crawford is CEO and co-founder of Pinnacle, a professional network for women in medicine. She completed her undergraduate at Auburn University obtaining a degree in Nutrition Science, Medical School at University of Texas Medical Branch, OBGYN Residency at University of Texas Southwestern, and REI Fellowship at University of North Carolina, concurrently obtaining a Master of Science in Clinical Research. Dr. Crawford is a digital health educator on social media, YouTube, and hosts the podcast “As a Woman: Fertility, Hormones and Beyond” with over 5 million downloads. Her debut book, “The Fertility Formula: Take Control of your Reproductive future”released by Penguin Random House April 2026 Unlike many physicians, Natalie has a whole body approach to medicine – fusing lifestyle and functional medicine with science backed facts to help people conceive and understand their bodies. Where To Find Dr. Natalie Crawford: Website: https://www.nataliecrawfordmd.com/Facebook: https://www.facebook.com/nataliecrawfordmd/ As a Woman Podcast: https://www.youtube.com/@asawomanpodcastInstagram: https://www.instagram.com/nataliecrawfordmd/?hl=enBook “The Fertility Formula”: https://www.nataliecrawfordmd.com/book

Actinomyces species are considered part of the normal vaginal and urogenital tract flora. The percentage of Pap smears containing Actinomyces-like organisms varies but is most commonly reported as approximately 7% among women using IUDs. That number is supported by multiple sources, including the Infectious Diseases Society of America guideline and several clinical studies. The incidence can be higher or lower depending on the type of IUD; for example, copper IUDs have been associated with rates up to 20%, while levonorgestrel-releasing IUDs show lower rates around 2.9%. In women with an IUD, who are found to have this finding on their liquid-based Pap smear, what is the appropriate management? In this episode, which comes from one of our podcast family members, we will discuss this topic and it's management in both symptomatic and symptomatic (pelvic pain) IUD wearing women. 1. McHugh KE, Sturgis CD, Procop GW, Rhoads DD. The Cytopathology of Actinomyces, Nocardia, and Their Mimickers. Diagnostic Cytopathology. 2017;45(12):1105-1115. doi:10.1002/dc.23816.2. Practice Bulletin No. 186: Long-Acting Reversible Contraception: Implants and Intrauterine Devices. Obstetrics and Gynecology. 2017;130(5):e251-e269. doi:10.1097/AOG.0000000000002400.3. Miller JM, Binnicker MJ, Campbell S, et al. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2024; ciae104. doi:10.1093/cid/ciae104.5. Carrara J, Hervy B, Dabi Y, et al. Added-Value of Endometrial Biopsy in the Diagnostic and Therapeutic Strategy for Pelvic Actinomycosis. Journal of Clinical Medicine. 2020;9(3):E821. doi:10.3390/jcm9030821.

Welcome to Fertility & Sterility Roundtable! Each week, we will host a discussion with the authors of "Views and Reviews" and "Fertile Battle" articles published in a recent issue of Fertility & Sterility.  This week, we welcome Dr. Richard Paulson and Dr. Jamie Kuhlman to discuss Restorative Reproductive Medicine (RRM) — a field that describes itself as focusing on identifying and treating the root causes of infertility rather than bypassing or suppressing natural reproductive processes. In this episode, we explore whether RRM represents a truly novel approach to fertility care, examine its religious and political influences, and consider the potential risks the movement poses to access to evidence-based fertility treatments, including IVF. Dr. Richard Paulson holds the Alia Tutor Chair in Reproductive Medicine and is Professor and vice-chair in the Department of Obstetrics and Gynecology at the University of Southern California, where he is also Director of the Fellowship in Reproductive Endocrinology and Infertility. He is past president of the American Society for Reproductive Medicine, and of the Pacific Coast Reproductive Society. Dr. Paulson has authored over 300 scientific articles and has received more than 35 awards for research and scientific presentations. He is the current Editor-in-Chief of "Fertility & Sterility Reports."  Dr. Kuhlman is a Licensed Psychologist and the Owner of Courageous Path Counseling, PLLC, in Nashville, TN. She specializes in infertility, postpartum, and maternal mental health through individual counseling and psychological evaluations for third-party reproduction. She is also a PRIMED Scholar with the American Society of Reproductive Medicine, focusing on advocacy within reproductive healthcare.  The unscientific nature of the arguments of "Restorative Reproductive Medicine" and why we need to understand them https://www.fertstertreports.org/article/S2666-3341(25)00111-4/fulltext The illusion of reproductive choice: how restorative reproductive medicine violates reproductive autonomy and informed consent https://www.fertstert.org/article/S0015-0282(25)00596-5/fulltext   View Fertility and Sterility at https://www.fertstert.org/  

Having data is sometimes different than having clinically applicable data. This is exactly the issue with the proposed plan to reduce surgical site infection (SSI) by changing surgical gloves after placental delivery at C-Section. Just 24 hours ago, we received the question from a PGY4 OBGYN resident asking whether the practice of changing surgical gloves at C-Section after placental delivery to reduce SSI was evidence-based. So, in this episode, we will review the data - which is timely since this was recently published on November 13, 2025 in the J Hospital Infection. This study follows a statement on this practice released by FIGO in September 2025. It's an interesting proposal, and there is clearly data in support of this, yet the ACOG and CDC do not recommend this practice as of Nov 2025. Is there a disconnect? Listen in for details. 1. FIGO: https://www.figo.org/news/new-ijgo-review-provides-comprehensive-framework-preventing-post-caesarean-sepsis (International Journal of Gynecology & Obstetrics)2. Stanberry B, Jordan L, Pullyblank A, Hargreaves J. Glove change during caesarean birth: impact on maternity service budgets and capacity. J Hosp Infect. 2025 Nov 13:S0195-6701(25)00354-8. doi: 10.1016/j.jhin.2025.10.033. Epub ahead of print. PMID: 41241232.3. Narice BF, Almeida JR, Farrell T, Madhuvrata P. Impact of Changing Gloves During Cesarean Section on Postoperative Infective Complications: A Systematic Review and Meta-Analysis. Acta Obstetricia Et Gynecologica Scandinavica. 2021;100(9):1581-1594. doi:10.1111/aogs.14161.4. Routine Sterile Glove and Instrument Change at the Time of Abdominal Wound Closure to Prevent Surgical Site Infection (ChEETAh): A Pragmatic, Cluster-Randomised Trial in Seven Low-Income and Middle-Income Countries.NIHR Global Research Health Unit on Global Surgery. Lancet (London, England). 2022;400(10365):1767-1776. doi:10.1016/S0140-6736(22)01884-0.5. Gialdini C, Chamillard M, Diaz V, Pasquale J, Thangaratinam S, Abalos E, Torloni MR, Betran AP. Evidence-based surgical procedures to optimize caesarean outcomes: an overview of systematic reviews. EClinicalMedicine. 2024 May 19;72:102632. doi: 10.1016/j.eclinm.2024.102632. PMID: 38812964; PMCID: PMC11134562.

In this episode of Money Tales, our guest is Dr. Julia Edelman. Today's guest is a trailblazing OB-GYN and menopause specialist who turned a frugal, hands-on childhood into a purpose-driven medical career. At a time when women in medicine were not taken seriously, or given the same opportunities, Julia persevered with grit and grace, proving that passion and persistence can pave the way for lasting impact. She shares how agency, determination, and clear values shaped her life choices, especially when money and medicine collided. About Julia Edelman: Menopause Practitioner of the Year Julia is a Yale graduate, Columbia Medical School graduate, Harvard residency-trained physician and a nationally recognized menopause expert. A board-certified gynecologist and Menopause Certified practitioner, she has been caring for women for over four decades and is highly regarded for her evidence-based compassionate approach to women's health. The founder of Women's Health and Gynecology of New England, Julia has trained and mentored physicians and medical students at Harvard and Brown medical schools. The North American Menopause Society awarded Dr. Edelman the honor of “Menopause Practitioner of the Year” after she published her first book Menopause Matters: Your Guide to a Long and Healthy Life. She followed with Successful Sleep Strategies for Women (Harvard Health Publications). Her new book, The Savvy Woman's Guide to Menopause: Before, During, and Beyond (Johns Hopkins University Press, October 2025) provides clear, practical guidance to help individuals navigate the physical, emotional, and cognitive changes of midlife and beyond with confidence. In addition, Julia runs The New England Center for Body Sculpting, which offers FDA approved noninvasive antiaging treatments and functional medicine treatments for men and women with no needles, no pain, and no downtime. Some treatments build muscle, permanently eliminate fat cells, and restore collagen and muscle strength in the abdomen, love handles and other areas. The Center also offers a noninvasive face treatment that restores collagen while smoothing and tightening the skin to give a natural, more youthful appearance.  And it has an Emsella chair or “Kegel chair”, that restores urine control for men and women. Inspired by Dr. Edelman's journey? Explore how values-driven conversations and clear decision-making can empower your career path and your relationship with money. Tune in to a podcast on Exciting & Creative Careers. If you'd like to speak with an Aspiriant advisor about aligning your financial plan with your goals and values, connect with us here. Subscribe to Money Tales on Spotify, Apple Podcasts, or YouTube Music for more inspiring stories about purpose, money and personal growth.

A New Podcast from Obstetrics & Gynecology, featuring members from the Editorial Team and contributing authors, each month as they highlight the latest research and practice updates in the field. This episode features an interview with Dr. Matthew Wagar, author of "Ultrasonography-Based Measurements of Endometrial Thickness in Patients With p53 Abnormal Endometrial Carcinomas."

Podcast Family, we have covered the subject of Measles previously on this show (links below). Those episodes were a preview of what has now been released ahead of print as a narrative review in the Green Journal! In this episode, we will summarize the KEY points of measles infection in pregnancy and re-state the “rule of 4” and the importance of the number 10 regarding this.1. Feb 24, 2025: Measles 101: https://open.spotify.com/episode/4lXrpqKTJPdDcTXPxpEmcb2. April 27, 2019: Measles!! ACOG Practice Advisory: https://creators.spotify.com/pod/profile/dr-hector-chapa/episodes/MEASLES---ACOG-practice-advisory-e3s1p43. Joseph, Naima T. MD, MPH. Measles in Pregnancy: Clinical Considerations and Challenges. Obstetrics & Gynecology ():10.1097/AOG.0000000000006126, November 14, 2025. | DOI: 10.1097/AOG.0000000000006126

Well, from time to time we cover RANDOM tidbits of information which cover RANDOM questions and/or RANDOM patient care issues that we encounter. In this episode we will cover one OB issue related to recurrent pregnancy loss, one GYN issue related to unilateral breast swelling in a patient with SLE, and one RANDOM life perspective response from a mock interview that I participated in for a residency candidate. Listen in fordetails!1.     Viviana DO; Giugni, Claudio Schenone MD; Ros, Stephanie T. MD, MSCI. Factor V and recurrent pregnancy loss: de Assis, Evaluation of Recurrent Pregnancy Loss. Obstetrics & Gynecology 143(5):p 645-659, May 2024. | DOI: 10.1097/AOG.0000000000005498Unilateral Breast Swelling with SLE: 2.     Voizard B, Lalonde L, Sanchez LM, et al. LupusMastitis as a First Manifestation of Systemic Disease: About Two Cases With a Review of the Literature. European Journal of Radiology. 2017;92:124-131. doi:10.1016/j.ejrad.2017.04.023.3.     Kinonen C, Gattuso P, Reddy VB. Lupus Mastitis:An Uncommon Complication of Systemic or Discoid Lupus. The American Journal of Surgical Pathology. 2010;34(6):901-6. doi:10.1097/PAS.0b013e3181da00fb.4.      Summers TA, Lehman MB, Barner R, Royer MC. Lupus Mastitis: A Clinicopathologic Review and Addition of a Case. Advances in Anatomic Pathology.2009;16(1):56-61. doi:10.1097/PAP.0b013e3181915ff7.5.     Jiménez-Antón A, Jiménez-Gallo D,Millán-Cayetano JF, Navarro-Navarro I, Linares-Barrios M. Unilateral Lupus Mastitis.Lupus. 2023;32(3):438-440. doi:10.1177/09612033221151011.STRONG COFFEE PROMO: 20% Off Strong Coffee Company https://strongcoffeecompany.com/discount/CHAPANOSPINOBG

The ACOG acknowledges that maternal obesity affects labor curves and recommends allowing more time for cervical dilation before diagnosing labor arrest in obese patients. This approach aims to avoid unnecessary interventions, such as premature cesarean delivery, which may occur if standard labor curves are strictly applied to obese women. In this episode, we will review a new study from the AJOG (08 Nov 2025) which describes labor progression and duration according to maternal body mass index, validating the need (possibly) for a BMI -based labor curve. Has there been advocates of a BMI-based labor curve? Listen in for details.1. Edwards, Sara et al. Characterizing Labor Progression and Duration According to Maternal Body Mass Index. American Journal of Obstetrics & Gynecology, Volume 0, Issue 02. Lundborg L, Liu X, Åberg K, et al. Association of Body Mass Index and Maternal Age With First Stage Duration of Labour. Scientific Reports. 2021;11(1):13843. doi:10.1038/s41598-021-93217-5.3. Kominiarek MA, Zhang J, Vanveldhuisen P, et al. Contemporary Labor Patterns: The Impact of Maternal Body Mass Index. American Journal of Obstetrics and Gynecology. 2011;205(3):244.e1-8. doi:10.1016/j.ajog.2011.06.014.4. Norman SM, Tuuli MG, Odibo AO, et al. The Effects of Obesity on the First Stage of Labor.Obstetrics and Gynecology. 2012;120(1):130-5. doi:10.1097/AOG.0b013e318259589c.

Ep. 396 Twins Untangled: The Data Behind Safe Twin Birth with Dr. Stu In this week's episode of The Birth Lounge Podcast, HeHe sits down with Dr. Stu Fischbein to unpack the truth about twin births, and it's probably not what your provider has told you. They dive into why C-sections have become the default for twins in the U.S. (hint: it's not because it's safer), and how our medical system continues to over-manage what can often be a normal variation of birth. Dr. Stu breaks down what's really happening with rising twin pregnancies, how assisted reproductive technology plays a role, and why evidence still supports vaginal twin births when handled by skilled providers. You'll hear them talk about: How to find a provider who's actually experienced with vaginal twin births The real deal on ECVs, breech twins, and what “mono-mono” and “mono-di” really mean How to advocate for your birth plan even when you're having multiples If you're expecting twins, or just want to understand how broken our twin birth system has become, this episode is your blueprint for making informed, confident choices and protecting your power in the birth room. 00:00 Introduction to Twin Births 01:07 Welcome to The Birth Lounge Podcast 01:14 Black Friday Sale Announcement 02:29 The Birth Lounge Overview 09:52 Special Guest: Dr. Stu Fischbein 10:21 Challenges and Misconceptions About Twin Births 11:25 Dr. Stu's Background and Expertise 12:48 Navigating Twin Births in the Medical System 14:15 The Importance of Informed Consent 15:51 Current Landscape of Twin Births 20:49 Training and Skills in Obstetrics 35:34 Risks and Realities of Twin Births 57:29 Legislation and Training in Midwifery 59:07 Economic Incentives in Birth Practices 01:00:16 Personal Experience with Baby Gear 01:03:31 Cost Analysis of C-Sections vs. Vaginal Births 01:04:50 Hospital Policies and C-Section Rates 01:08:44 Historical Perspective on Birth Practices 01:14:08 Twin Births: Hospital vs. Home 01:20:30 Challenges in Breech Deliveries 01:24:27 External Cephalic Version (ECV) Insights 01:30:42 Timing and Risks in Twin Deliveries 01:40:07 Final Thoughts and Advice for Expecting Mothers   Guest Bio: Stuart J. Fischbein MD is a community-based obstetrician and an Associate of the American College of Obstetrics & Gynecology, published author of the book “Fearless Pregnancy, Wisdom & Reassurance from a Doctor, A Midwife and A Mom” and peer-reviewed papers Homebirth with an Obstetrician, A Series of 135 Out of Hospital Births and Breech birth at home: outcomes of 60 breech and 109 cephalic planned home and birth center births. After completing his residency at Cedars-Sinai Medical Center in Los Angeles, CA, Dr. Stu spent 24 years assisting women with hospital birthing and, for the last 13 years, has been a homebirth obstetrician who works directly with midwives. Since retiring from attending home births in 2022, Dr. Stu has turned his focus to traveling around the world as a lecturer and advocate for reteaching breech & twin birth skills, respect for the normalcy of birth and honoring informed consent. He hosts a weekly podcast with co-host Blyss Young and together they offer hope, reassurance and safe, honest evidence supported choices for those women who understand pregnancy is a normal bodily function not to be feared. Follow him on Instagram @birthinginstincts. His websites are www.birthinginstincts.com & www.birthinginstinctspodcast.com INSTAGRAM: Connect with HeHe on IG  Connect with Dr. Stu on IG    BIRTH EDUCATION: Join The Birth Lounge here for judgment-free childbirth education that prepares you for an informed birth and how to confidently navigate hospital policy to have a trauma-free labor experience!   Download The Birth Lounge App for birth & postpartum prep delivered straight to your phone!   LINKS/RESOURCES MENTIONED: Check out our episode with Dr. Stu's cohost, Blyss Young (ep. 232)    Listen to episode 179 with Dr. Rixa Freeze    Here's a link to the Primitive Reflexes episode Dr. Stu references   https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0313941   www.birthinginstincts.com   https://podcasts.apple.com/us/podcast/birthing-instincts/id1552816683   www.birthinginstinctspodcast.com   https://pubmed.ncbi.nlm.nih.gov/30305050/   https://static1.squarespace.com/static/52ca1028e4b05c5f2d7b157d/t/62e02090874eae67b683bc67/1658855570428/A+Maneuver+for+Head+Entanglement+Published.pdf

Today we have Dr. Marina Walther-Antonio, a Mayo Clinic researcher who investigates the role of the microbiome in cancer and reproductive health, particularly endometrial and ovarian cancers. According to the World Cancer Research Fund International, endometrial and ovarian cancers are among the top 10 most prevalent cancers in women worldwide, and there are still no standard screenings for early detection. Marina is an assistant professor in the Department of Surgery and the Mayo Clinic Center for Individualized Medicine Microbiome Program. She has a joint appointment in the department of Obstetrics and Gynecology. Today we talk to Marina about how she and her colleagues are utilizing the methodologies of environmental microbiology and technologies used in astrobiology to improve our understanding of endometrial and ovarian cancers. Through her investigations into the microbiome, she and her team are developing early detection tests that will enable clinical interventions before certain cancers develop. Show notes: [00:03:13] Dawn opens our interview asking Marina about the history of her interest in extraterrestrial life. [00:05:49] Dawn mentions that Marina did her undergraduate studies in Portugal at the University of Aveiro, where she majored in biology. Dawn asks why Marina chose biology as her major. [00:06:39] Ken explains that the undergraduate programs at Aveiro University require students to do a year of research outside the university and asks Marina about her experience with this requirement. [00:08:34] Ken explains that while Marina was conducting her internship at NASA Ames Research Center, there were several projects under way at the astrobiology institute, with the one that Marina was assigned to looking at a Mars analogue site in Oregon's Warner Valley. Ken asks what kind of work Marina did on this project. [00:10:06] Ken asks Marina why after earning a master's degree in microbiology from Indiana University, she went to Washington State University to earn a Ph.D. in environmental sciences. [00:13:29] Dawn asks about Marina's Ph.D. research on microbialites, which are microbial structures that can thrive at the bottom of certain freshwater lakes and other extreme environments. [00:16:02] Dawn explains that just as Marina began researching microbial populations, the Mayo Clinic Center for Individualized Medicine created a microbiome program. Dawn asks Marina about the circumstances that led to her joining Mayo. [00:19:05] Dawn mentions that Dr. Claire Fraser, the director of Maryland's Institute for Genome Sciences pointed out in Episode 32 of STEM-Talk that there are more microbes on a single person's hands than there are people on Earth, as well as the fact that our gut is home to more than 100 trillion bacteria. Dawn asks Marina to talk about this microbial side of humanity. [00:21:51] Ken mentions that if listeners are interested in learning more about the microbiome and how it affects human health, they should listen to Episodes 20 and 168 with Dr. Alessio Fasano. Ken asks Marina to give a short overview of the microbiome. [00:25:37] Dawn asks Marina how the focus of her research shifted to the role of the microbiome in cancer and reproductive health. [00:29:00] Dawn explains that endometrial and ovarian cancers are among the top 10 most prevalent cancers in women worldwide; with ovarian cancer being the most common gynecological malignancy and the fifth leading cause of death due to cancer in women in the nation. Dawn goes on to explain that in a 2023 paper Marina investigated the area of microbiome that is associated with ovarian cancer to better understand the microbiome's potential in early detection. Dawn asks Marina to talk about this study and its findings. [00:35:55] Given the small scale and sample size of her initial study, Ken asks Marina what her ideal follow-up study would look like. [00:38:37] Ken mentions that in 2019 Marina published the r...

Taking folic acid prior to conception and during pregnancy can help protect the unborn baby from developing abnormalities. Supplements are particularly important for women who have epilepsy, as anti-seizure medication (previously known as anti-convulsants or anti-epileptic drugs) can lead to a deficiency in folic acid. Until 2023, high doses of 4-5 mg per day were recommended. However, this has changed as the data has changed. Did you know the SMFM no longer recommends “high dose” folic acid preconceptionally for patients on seizure medications? This is also highlighted in a recently released epub from Obstetrics and Gynecology (Green Journal) on October 31, 2025. Listen in for details. 1. Mokashi, Mugdha MD, MPH; Cozzi-Glaser, Gabriella MD; Kominiarek, Michelle A. MD, MS. Dietary Supplements in the Perinatal Period. Obstetrics & Gynecology ():10.1097/AOG.0000000000006098, October 31, 2025. | DOI: 10.1097/AOG.00000000000060982. Asadi-Pooya AA. High dose folic acid supplementation in women with epilepsy: are we sure it is safe? Seizure. 2015 Apr;27:51-3. doi: 10.1016/j.seizure.2015.02.030. Epub 2015 Mar 7. PMID: 25891927.3. https://aesnet.org/about/aes-press-room/press-releases/guideline-issued-for-people-with-epilepsy-who-may-become-pregnant4. Turner C, McIntosh T, Gaffney D, Germaine M, Hogan J, O'Higgins A. A 10-year review of periconceptual folic acid supplementation in women with epilepsy taking antiseizure medications. J Matern Fetal Neonatal Med. 2025 Dec;38(1):2524094. doi: 10.1080/14767058.2025.2524094. Epub 2025 Jun 30. PMID: 40588438.5. https://www.aan.com/PressRoom/Home/PressRelease/5170#:~:text=The%20guideline%20recommends%20that%20people,and%20possibly%20improve%20neurodevelopmental%20outcomes.6. https://aesnet.org/about/aes-press-room/press-releases/guideline-issued-for-people-with-epilepsy-who-may-become-pregnant

Dealing with menopause symptoms is rough enough, but navigating a cancer diagnosis at the same time causes even more stress and anxiety.  As a holistic-focused physician going through menopause, a diagnosis of breast cancer put a bump in the road for Dr. Suzanne Gilberg-Lenz, leading to concerns about how she would navigate her own journey.  It can be hard to feel heard by your physician, and advocating for things like holistic healing options, lab testing, and hormone replacement therapy can become an endless battle. But as a women's empowerment advocate and a public educator, Dr. Suzanne is here today to help YOU advocate for your needs and to speak up about your situation because you deserve to be heard.  Hearing Dr. Suzanne's story can help you get through any tough times you're facing. Especially for the breast cancer community– there are ways you can manage your longevity and your health now going forward for the better. Check out this podcast to find out how!  Suzanne Gilberg-Lenz, MD  Dr. Suzanne Gilberg-Lenz earned her medical degree from the USC School of Medicine and completed her residency in Obstetrics and Gynecology at UCLA/Cedars-Sinai Medical Center. She frequently appears as an expert in women's health and integrative medicine in print, online, and on TV, where she's the Chief Medical Correspondent for the Drew Barrymore Show. She's the author of MENOPAUSE BOOTCAMP: Optimize Your Health, Empower Your Self, and Flourish as You Age.  IN THIS EPISODE Dr. Suzanne's perimenopause and menopause journey  Opening up about a breast cancer diagnosis Recognizing symptoms of perimenopause vs. other health issues  Non-negotiables for women's health in our 40s and beyond  Hormone therapy options in midlife  Advocating for yourself with your primary physician  Adaptogenic herbs that are helpful in midlife  Stress, sleep, and cardiometabolic tips for optimal health  Grassroots and community building via the Menopause Bootcamp Facilitator Certification  RESOURCES MENTIONEDUse code ENERGIZED and get $100 off on your CAROL Bike purchase https://carolbike.pxf.io/GK3LaE Menopause Bootcamp Certification Course  Get 20% off with Code: Energized20 Get Dr. Suzanne's book HERE: Menopause Bootcamp  Dr. Suzanne's Website Dr. Suzanne's Socials:  Facebook Instagram  TikTok YouTube  RELATED EPISODES  #590: Dispelling Myths About Breast Cancer And Mammograms + Navigating Hrt After Breast Cancer With Dr. Jenn Simmons 579: Hormone Replacement Options And Hormone Testing For Women In Midlife + Self Advocacy For Optimal Health With Esther Blum #547: What You Need To Know About The Opill And Hormone Changes In Perimenopause With Dr. Carrie Jones #404: Do Women Need To Wait Till Menopause To Begin Hormone Replacement Therapy? With Esther Blum

Elinzanetant, sold under the brand name Lynkuet, receivedapproval from the U.S. Food and Drug Administration (FDA) on October 24, 2025, for the treatment of moderate to severe hot flashes due to menopause.  How is this different than Fezolinetant, which was approved in 2023? Listen in for details. 1.   Menegaz de Almeida, Artur MS; Oliveira, Paloma MS; Lopes, Lucca MD; Leite, Marianna MS; Morbach, Victória MS; Alves Kelly, Francinny MD; Barros, Ítalo MS; Aquino de Moraes, Francisco Cezar MS; Prevedello, Alexandra MD. Fezolinetant and Elinzanetant Therapy for Menopausal Women Experiencing Vasomotor Symptoms: A Systematic Review and Meta-analysis. Obstetrics & Gynecology 145(3):p 253-261, March 2025. | DOI: 10.1097/AOG.00000000000058122.     Pinkerton JV, Simon JA, Joffe H, Maki PM, NappiRE, Panay N, Soares CN, Thurston RC, Caetano C, Haberland C, Haseli Mashhadi N, Krahn U, Mellinger U, Parke S, Seitz C, Zuurman L. Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: OASIS 1 and 2 Randomized Clinical Trials. JAMA. 2024 Aug 22;332(16):1343–54. doi: 10.1001/jama.2024.14618. Epub ahead of print. PMID: 39172446; PMCID: PMC11342219.3.     Cardoso F, Parke S, Brennan DJ, Briggs P,Donders G, Panay N, Haseli-Mashhadi N, Block M, Caetano C, Francuski M, Haberland C, Laapas K, Seitz C, Zuurman L. Elinzanetant for Vasomotor Symptomsfrom Endocrine Therapy for Breast Cancer. N Engl J Med. 2025 Aug 21;393(8):753-763. doi: 10.1056/NEJMoa2415566. Epub 2025 Jun 2. PMID: 40454634.STRONG COFFEE PROMO: 20% Off Strong CoffeeCompany https://strongcoffeecompany.com/discount/CHAPANOSPINOBG

We challenge the band-aid approach to women's midlife health and show how faith and functional medicine uncover root causes behind hormones, fatigue, and heavy periods. We separate myth from evidence on HRT and give clear first steps to advocate for lasting change.• why conventional gynecology misses upstream causes• burnout, back pain, and a pivot to functional medicine• the mindset shift from insurance-driven fixes to real healing• heavy periods, IUD risks, and synthetic progestin concerns• functional medicine's timeline and root-cause method• estrogen versus progestins and WHI study context• safer, bioidentical HRT paired with lifestyle repair• practical first steps to self-advocacy and hope• inviting God into the healing journeyCHECK OUT THE ENTIRE MIDLIFE RESET SUMMIT!! https://midliferesetsummit.com/Did you know over 6,000 women enter menopause every single day in the U.S. ? The medical system isn't helping them heal at the root — and that's where faith-based coaches come in.

On January 18, 2020, we released an episode called “Vaginal Vit C for BV? Yep, it's DATA”. That was 5 years ago! Now, in the Green Journal, a new systematic review and meta-analysis is examining this subject….AGAIN. Plus, this is not the only systematic review to investigate this; a similar review was published in Acta Obstétrica e Ginecológica Portuguesa earlier this year (2025) in March. So, did we get it right 5 years ago? Can vaginal Vit C help in eliminating BV? Listen in for details!1. Khaikin, Yannay MD; Elangainesan, Praniya MD, MSc; Winkler, Eliot MD, MSc; Liu, Kuan PhD, MMath; Selk, Amanda MD, MSc; Yudin, Mark H. MD, MSc. Intravaginal Vitamin C for the Treatment and Prevention of Bacterial Vaginosis: A Systematic Review and Meta-analysis. Obstetrics & Gynecology ():10.1097/AOG.0000000000006092, October 23, 2025. | DOI: 10.1097/AOG.0000000000006092; https://journals.lww.com/greenjournal/pages/articleviewer.aspx?year=9900&issue=00000&article=01389&type=Fulltext2. Acta Obstétrica e Ginecológica Portuguesa (March 2025): chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://scielo.pt/pdf/aogp/v19n1/1646-5830-aogp-19-01-40.pdf3. Chapa Clinical pearls 2020: https://podcasts.apple.com/gh/podcast/vaginal-vit-c-for-bv-yep-its-data/id1412385746?i=1000463002444

I was recently asked to OPINE on the labor management for a patient who was receiving IV Pitocin for augmentation, who experienced a placental abruption. One physician stated that in "his opinion", Pitocin increased the risk of placental abruption intrapartum, a point which the original treating physician refuted. So, I was asked to be the "referee" on the play. IV Pitocin can result in some maternal-fetal complications but is abruption one of them as a stand-alone complication. Was the first reviewer's opinion correct? Listen in for details.1. Ben-Aroya Z, Yochai D, Silberstein T, Friger M, Hallak M, Katz M, Mazor M. Oxytocin use in grand-multiparous patients: safety and complications. J Matern Fetal Med. 2001 Oct;10(5):328-31. doi: 10.1080/714904358. PMID: 11730496.2. Morikawa M, Cho K, Yamada T, et al. Do Uterotonic Drugs Increase Risk of Abruptio Placentae and Eclampsia? Archives of Gynecology and Obstetrics. 2014;289(5):987-91. doi:10.1007/s00404-013-3101-8.3. ACOG: First and Second Stage Labor Management: ACOG Clinical Practice Guideline No. 8. Obstetrics and Gynecology. 2024;143(1):144-162. doi:10.1097/AOG.0000000000005447.4. Pitocin. FDA Drug Label. Food and Drug Administration Updated date: 2024-08-125. Litorp H, Sunny AK, Kc A. Augmentation of Labor With Oxytocin and Its Association With Delivery Outcomes: A Large-Scale Cohort Study in 12 Public Hospitals in Nepal.Acta Obstetricia Et Gynecologica Scandinavica. 2021;100(4):684-693. doi:10.1111/aogs.13919.

About this episode: Prescribing medicine to address fever or pain in pregnancy is a delicate task with a need to consider both potential benefits and risks. In this episode: Obstetrician Dr. Angie Jelin shares how she discusses Tylenol use with expectant parents in the context of emerging evidence and recent news from the federal government. Guests: Dr. Angie Jelin is the assistant director of prenatal genetics at the Prenatal Diagnostic Center in the Division of Maternal-Fetal Medicine and an assistant professor in the Johns Hopkins Medicine Department of Gynecology and Obstetrics. Host: Dr. Josh Sharfstein is distinguished professor of the practice in Health Policy and Management, a pediatrician, and former secretary of Maryland's Health Department. Show links and related content: Autism Risk Linked to Fever During Pregnancy—Columbia Mailman School of Public Health Interpreting the Data on Tylenol, Pregnancy, and Autism—Public Health On Call (September 2025) Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

There is very little in the practice of holistic health that has escaped the attention of Dr. Christiane Northrup over the past quarter-century. Christiane has experienced the huge highs as a highly successful New York Times best-selling author and a favorite of many (including Oprah Winfrey) to the dark days of COVID when her once-coveted advice was censored and ignored.Fortunately, none of the recent pushback has silenced Dr. Christiane Northrup who describes a plandemic gone bad and all of the problems associated with women's health, including the misuse of synthetic hormones, this week on Spirit Gym.Learn more about the asset-based sharing system for gold and silver ownership that Paul and Dr. Northrup talked about here.Learn more about Christiane and her work on her website and her product line for hormonal balance at Amata Life. Find her on social media via Truth Social, Facebook, Twitter/X, YouTube, Rumble, Instagram and Telegram along with Substack. Download her free Should You Try Herbs to Support the Change ebook at this link.Timestamps9:22 Christiane's decision to go to medical school was based partly on how the established medical system was failing her family.12:12 Focusing on obstetrics and gynecology and being with pregnant women was what Christiane was designed by God to do.20:54 Many bodily problems women suffer from are their way of expressing their distress.30:03 Why do women living in the Western world suffer from so many bad symptoms associated with menopause?46:35 “If you did things to animals that we do to humans [at birth], the mother would reject the cubs.”1:04:03 How the chapter of John in the Bible fits well with the message of The Matrix Trilogy.1:15:59 Christiane's take on the countless ways so many handled/orchestrated COVID so very badly.ResourcesFind  all resources for this episode on our website.Music Credit: Meet Your Heroes (444Hz), Composed, mixed, mastered and produced by Michael RB Schwartz of Brave Bear MusicThanks to our awesome sponsors:PaleovalleyBIOptimizers US and BIOptimizers UK PAUL15Organifi CHEK20Wild PasturesKorrect SPIRITGYMPique LifeCHEK Institute/CHEK AcademyPaul's Dream Interpretation workshop We may earn commissions from qualifying purchases using affiliate links.